SEARCH   
 
Manufacturing Base

 

Beijing Luzhu Biopharmaceutical Co. Ltd (Luzhu), founded in October 2003 with 10 million RMB registered capital, is located in Beijing Economic-Technological Development Area, covering an area of 16,005 m2. Wholly owned by Zhifei(SZSE:300122), and involved in R&D, manufacture and marketing, it is a hi-tech enterprise granted by Beijing municipality.
In June 2005, Luzhu was issued the Pharmaceutical Manufacture Licence by Beijing Drug Administration (BJDA). Since 2007, it obtained  the drug approval documents of "meningococcal A/C conjugate vaccine" and "A, C, Y, W135 meningococcal polysaccharide vaccine" successively as well as GMP certificates. Since marketed in 2008, both products have brought significant growth in social and economic benefits.
Luzhu implements startegy of promoting enterprise development by independent R&D. It has submitted 9 NDAs to SFDA, 5 of which have completed phase III clinical trials and are applying for drug approval document. Another 5 new bioproducts are in different R&D stages.  With efforts of a Hi-tech  R&D talent team, Luzhu acquired funding from multiple channels including "863 program", "New Drug Research and Development" program by Ministry of Science and Technology.

 

AnHui Longcom Biologic Pharmacy Co., Ltd(Longcom), a hi-tech enterprise engaged in developing, manufacturing and marketing biological products, is 100% owned by Zhifei.  It possesses standardized freeze-dried production workshop with advanced equipment supported with full-featured animal testing center, quality testing center, as well as storage facilities and office environment. Longcom successfully obtained GMP certificates in 2000 and in 2007 respectively.
The leading product of Longcom, Vaccae, (Mycobacterium vaccae for injection), was co-developed by National Institute for the Control of Drugs and Biological Products and 309 Hospital of PLA, and Anhui Longcom Biologic Pharmacy Co.,Ltd. Vaccae, a bi-directional immunomodulator, which can significantly enhance immune function and relieve hypersensitivity at the same time, is mainly used for the treatment of tuberculosis and other
immunotherapies, especially playing a significant role in refractory or relapsing TB.  Noticeably, vaccae is the only recommended agent of World Health Organization (WHO) in the treatment of TB and has been listed as national "Tenth Five-year" major scientific research project administration. What‘s more, vaccae also shows good prospects in treatment of bronchial asthma, allergic rhinitis, hepatitis B and so on. The company is trying hard to expand its indications with a firm belief that within years it can generate great benefits both socially and economically.
Honors:
State Planning Commission---Demonstration Project of Hi-tech Industrialization
State Economic and Trade Commission--- National Trial Production Project of Key & New Products
Ministry of Science---National Torch Planning Project
Ministry of Science---National Science and Technology Innovation Fund